Company news
Prostatype Genomics AB news in 2026
Prostatype Genomics AB's news releases, calls and decks from 2026, newest first.
Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6
September 17, 2026
Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6
August 31, 2026
Prostatype Genomics AB resolves on a directed issue
August 5, 2026
Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7
August 3, 2026
Prostatype Genomics AB announces outcome in rights issue of units
July 27, 2026
Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026
July 21, 2026
The subscription period in Prostatype Genomics AB's rights issue of units begins today
July 9, 2026
Prostatype Genomics AB publishes information memorandum prior to rights issue of units
July 8, 2026
Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units
July 8, 2026
Prostatype Genomics provides financing update
June 30, 2026
The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million
June 29, 2026
Prostatype Genomics publishes Annual Report for 2025
June 1, 2026
Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million
May 19, 2026
Prostatype Genomics publishes year-end report for 2025
February 26, 2026
Loan financing of SEK 10 million to Prostatype Genomics AB
January 12, 2026